Aflibercept
Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and the European Union. It is an inhibitor of vascular endothelial growth factor (VEGF).
ATC code L01ATC code L01XX44ATC code S01ATC code S01LA05ATCvet code QL01XX44ATCvet code QS01LA05Anti–vascular endothelial growth factor therapyBayerBrolucizumabC4318H6788N1164O1304S32Central retinal vein occlusionColorectal cancerConberceptDiabetic retinopathyEyleaFOLFIRIFusion proteinGenzymeIntravitreal administrationIntravitreal injectionLeonard SchleiferList of antineoplastic agentsList of drugs: Ad–AkList of drugs granted breakthrough therapy designationList of largest selling pharmaceutical productsMacular degenerationMacular edemaMedication-related osteonecrosis of the jawPeter BachProtein kinase inhibitorPseudoxanthoma elasticumRanibizumabRegeneron PharmaceuticalsSanofiVascular endothelial growth factorZaltrapZiv-aflibercept
Link from a Wikipage to another Wikipage
primaryTopic
Aflibercept
Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and the European Union. It is an inhibitor of vascular endothelial growth factor (VEGF).
has abstract
Aflibercept (Handelsname Eylea ...... ofi vermarktet und vertrieben.
@de
Aflibercept (merknaam: Zaltrap ...... eptor-gemedieerde signalering.
@nl
Aflibercept è una proteina chi ...... nti 40 mg di principio attivo.
@it
Aflibercept, sold under the br ...... othelial growth factor (VEGF).
@en
El aflibercept es uno de los a ...... iones para mantener la visión.
@es
L'aflibercept, commercialisé s ...... ancer colorectal métastatique.
@fr
افليبيرسيبت هو دواء صيدلاني بي ...... ب اتفاق تم توقيعه في عام 2006.
@ar
アフリベルセプト（Aflibercept）は、バイオ医薬品と ...... れる場合があるが、英国では費用対効果がないとされ却下された。
@ja
alternative name
Eylea, Zaltrap
@en
CAS number
862111-32-8
FDA UNII code
15C2VL427D
KEGG
MedlinePlus
Link from a Wikipage to an external page
Wikipage page ID
17,545,444
page length (characters) of wiki page
Wikipage revision ID
983,211,018
Link from a Wikipage to another Wikipage
ATC prefix
L01
@en
ATC suffix
XX44
@en
CAS number
ChemSpiderID
none
@en
DailyMedID
Aflibercept
@en
Drugs.com
Aflibercept
@en
Ziv-aflibercept
@en
KEGG
D09574
@en
legal AU
S4
@en
legal EU
Rx-only
@en
legal status
Rx-only
@en
legal US
Rx-only
@en
licence EU
yes
@en
licence US
Aflibercept
@en
MedlinePlus
a612004
@en
pregnancy AU
D
@en
pregnancy category
Not recommended
@en
pregnancy US
C
@en
routes of administration
synonyms
ziv-aflibercept
@en
tradename
Eylea, Zaltrap
@en
Verifiedfields
changed
@en
verifiedrevid
477,243,410
Watchedfields
changed
@en
wikiPageUsesTemplate
subject
hypernym
comment
Aflibercept (Handelsname Eylea ...... ofi vermarktet und vertrieben.
@de
Aflibercept (merknaam: Zaltrap ...... en brede blokkade van de recep
@nl
Aflibercept è una proteina chi ...... nti 40 mg di principio attivo.
@it
Aflibercept, sold under the br ...... othelial growth factor (VEGF).
@en
El aflibercept es uno de los a ...... iones para mantener la visión.
@es
L'aflibercept, commercialisé s ...... ancer colorectal métastatique.
@fr
افليبيرسيبت هو دواء صيدلاني بي ...... ب اتفاق تم توقيعه في عام 2006.
@ar
アフリベルセプト（Aflibercept）は、バイオ医薬品と ...... れる場合があるが、英国では費用対効果がないとされ却下された。
@ja
label
Aflibercept
@de
Aflibercept
@en
Aflibercept
@es
Aflibercept
@fr
Aflibercept
@it
Aflibercept
@nl
أفليبيرسيبت
@ar
アフリベルセプト
@ja